Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 11—November 2004
ICWID Session Summaries

Group B Strep: Successful Model of "From Science to Action"1

Janine Cory*Comments to Author , Stephanie Schrag*, Mara J. Dinsmoor†, and Anne Schuchat*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Evanston Northwestern Hospital, Evanston, Illinois, USA

Suggested citation for this article

This panel session on the prevention of perinatal group B streptococcal disease (GBS) offered three perspectives on the history of the disease as an emerging concern in the United States. The panel addressed how recent epidemiologic research has effected a change in screening policy and a reduction in disease incidence, as well as the ongoing and future challenges presented by this disease.

Perspective on U.S. Transformation and Global GBS Needs

The session opened with an overview of GBS epidemiology and policy, demonstrating progress that has been made since screening recommendations were created in the early 1990s, including a consensus statement issued in 1996. Since then, GBS has dramatically declined. Further evidence led the Centers for Disease Control and Prevention to issue universal screening policy guidelines in 2002. The guidelines were a transition from the risk-based and screening-based strategies used earlier. As guidelines become more firmly entrenched as part of current obstetric care, new data must be collected to determine whether the trend of the past few years toward a plateau in screening efficacy, with particular distinctions between black and white women, will be eliminated by the new universal screening guidelines.

Obstetric Perspective on GBS Progress and Remaining Challenges

An obstetrician's point of view on the history of GBS detection and treatment and the current challenges in enacting a change in policy was presented. While screening and treatment rates rise, do adverse effects of intrapartum antibiotics, including antibiotic resistance or neonatal Escherichia coli sepsis, also increase? Also reiterated was the need to continue to educate clinicians, both obstetricians and pediatricians, to help keep GBS identification and treatment in perspective.

How Science, Advocacy, and Policy Help Women and Children

To offer a historic perspective of the successes and challenges posed by incorporating epidemiologic evidence into everyday policy, the session closed with a discussion of how political timing, advocacy groups, dedicated researchers, and skillful partnership development all have interacted simultaneously. As key surveillance revealed the epidemiologic picture of GBS, other factors played equally important roles in helping bring the science of GBS into the political limelight, which resulted in an active change in screening policy. GBS policy has the advantage of being firmly linked to a true reduction in disease; since 1993, >39,000 cases of GBS are estimated to have been prevented. As a working model of prevention, GBS policy continues to evolve to address ongoing issues.


Suggested citation for this article: Cory J, Schrag S, Dinsmoor MJ, Schuchat A. Group B strep: successful model of "From Science to Action" [conference summary]. Emerg Infect Dis [serial on the Internet]. 2004 Nov [date cited].

DOI: 10.3201/eid1011.040653_03

1The following comments were made in presentations by the above authors at the International Conference on Women and Infectious Disease.

Table of Contents – Volume 10, Number 11—November 2004

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Janine Cory, Centers for Disease Control and Prevention, Mailstop D65, 1600 Clifton Road, N.E., Atlanta, GA, 30333, USA; fax: 404-371-5445

Send To

10000 character(s) remaining.


Page created: April 17, 2012
Page updated: April 17, 2012
Page reviewed: April 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.